Drug Database
HE

hepatitis-A/typhoid vaccine (Hepatyrix)

✓ Approved

GSK · Vaccine · Vaccine

What is hepatitis-A/typhoid vaccine?

hepatitis-A/typhoid vaccine is a vaccine developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesHepatyrix
CompanyGSK
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

hepatitis-A/typhoid vaccine is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsTyphoid fever✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

Synergistic Grain Boundary and Phonon Engineering Enables Ultrahigh Thermoelectric Performance in Mg3(Sb, Bi)2-Based Materials.

Lei Jingdan J, Xu Kai K, Zhao Kunpeng K, Zhou Junzhuo J et al.

Thermoelectric Mg3(Sb, Bi)2 has emerged as a rising star in virtue of its promising thermoelectric performance and abundant constituent elements. However, its practical application is hindered by challenges in synthesis and the strong coupling between electrical and thermal transport properties. Herein, we propose a dual-pronged strategy that combines grain boundary engineering and phonon engineering to decouple electron and phonon transport in Mg3(Sb, Bi)2. By employing a tantalum-tube encapsulated melting technique together with Cu doping, the grain size is markedly increased to ∼25 µm, effectively suppressing carrier grain boundary scattering and enabling single-crystal-like electrical transport with a high carrier mobility exceeding 200 cm2 V-1 s-1. Meanwhile, atomic-scale alloy disorder and nanoscale Mg2Cu precipitates introduce strong phonon scattering, leading to an ultralow lattice thermal conductivity of 0.36 W m-1 K-1. Eventually, a peak zT of 1.9 at 750 K and a high conversion efficiency of 10.6% at ΔT = 488 K are achieved, demonstrating the competitive performance of these materials and devices. This study not only provides new insights into the manipulation of grain boundary scattering, but also demonstrates the great promise of Mg3(Sb, Bi)2 for waste-heat harvesting.

PubMedThe American journal of the medical sciences2026-08-30

The Evolving Burden of Hepatitis B and C: Past Trends and Future Projections from the Global Burden of Disease Study 2021.

Chen Yue Y, Mao He-Hui HH, Zhang Ming-Jing MJ, Zhang Jin-Yan JY et al.

Hepatitis B and C continue to pose significant challenges to global public health, and this study is aimed at evaluating their burden. Leveraging data from the Global Burden of Disease 2021, we analyzed age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life year rates (ASDRs) for hepatitis B and C from 1990 to 2021 using Joinpoint regression, age-period-cohort models, and decomposition analysis. Bayesian age-period-cohort models were applied to project future trends up to 2036. Additionally, we assessed the burden attributable to modifiable risk factors and its association with socioeconomic indicators. From 1990 to 2021, the global ASMR for hepatitis B declined from 12.19 to 7.57 per 100,000, and the ASMR for hepatitis C decreased from 8.18 to 6.10 per 100,000. Despite these decreases, the absolute numbers of deaths and DALYs continued to increase, mainly driven by population growth and aging. In 2021, males carried a disproportionately higher burden of hepatitis B and C compared to females. Moreover, countries with low socioeconomic development faced a greater burden. Notably, high alcohol consumption accounted for 16.20% of hepatitis B DALYs, while drug use was responsible for 49.49% of hepatitis C DALYs. By 2036, ASMRs are projected to decline further to 5.90 per 100,000 for hepatitis B and 5.23 per 100,000 for hepatitis C. Although ASMRs and ASDRs have declined, the global burden of hepatitis B and C remains considerable. Continued efforts in vaccination, antiviral treatment, and control of key risk factors are crucial, especially in populations with a high burden.

PubMedKidney medicine2026-08-30

COVID-19 Vaccine Knowledge, Practice, and Attitudes Among Hemodialysis Patients in Egypt, Kenya, and Cameroon: A Multicenter Study.

Elsayed Enass E, Kotb Khaled M KM, Heiba Ahmed A, Elhussini Manal Shaker MS et al.

Patients receiving hemodialysis (HD) are at increased risk of severe coronavirus disease 2019 (COVID-19) and were prioritized for vaccination, yet vaccine hesitancy remains common. We assessed COVID-19 vaccine knowledge, acceptance, and attitudes among patients receiving HD in Egypt, Kenya, and Cameroon and identified factors associated with vaccine acceptance, prior infection, willingness to receive future doses, and postvaccination complications. Multicenter cross-sectional survey study. Between March 2021 and April 2022, 765 patients receiving maintenance HD and 196 non-dialysis controls were recruited from dialysis centers in Egypt, Kenya, and Cameroon. Sociodemographic characteristics, clinical comorbidities, prior COVID-19, sources of vaccine information, and exposure to vaccinated or infected relatives. COVID-19 vaccine acceptance, willingness to receive future doses, prior infection, and post-vaccination complications. Structured questionnaires assessed knowledge, practices, and attitudes toward COVID-19 vaccination. Multivariable logistic regression identified factors independently associated with study outcomes. Vaccine acceptance was lower among patients receiving HD than nondialysis controls (58.2% vs 96.2%). Fear of side effects was the most common reason for refusal (39.3%). Postvaccination complications were less frequent among patients receiving HD (22.3% vs 44.3%). Hesitancy was more common among women, younger participants, and those with comorbidities or no prior COVID-19. Having vaccinated or previously infected relatives was associated with a greater willingness to receive future doses. Cross-sectional design limits causal inference. Nonprobability sampling and unmatched controls may limit generalizability. COVID-19 cases may have been underreported because of limited testing. COVID-19 vaccine hesitancy among patients receiving HD is driven by fear, misinformation, and sociodemographic factors. Targeted education and improved access to reliable vaccine information may help increase uptake in this population.

PubMedEMBO molecular medicine2026-08-30

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

Liu Lijie L, Yan Mengrong M, Liang Ruoxu R, Wu Qingxin Q et al.

Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.

PubMedRheumatology advances in practice2026-08-30

Coexisting juvenile idiopathic arthritis and autoimmune hepatitis type 1 in a child.

Oweidat Majd M, Smerat Sojoud H SH, Abunejma Fawzy M FM, Lehroob Jihad J

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hepatitis-A/typhoid vaccine